StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research note released on Friday morning. The brokerage issued a hold rating on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research report on Thursday, May 9th. […]
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that its VP of Business.
Can-Fite BioPharma (NYSE:CANF) Coverage Initiated by Analysts at StockNews.com modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, is pleased to invite investors to a.